Ginkgo Bioworks/$DNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ginkgo Bioworks
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Ticker
$DNA
Sector
Primary listing
NYSE
Employees
834
Headquarters
Website
Ginkgo Bioworks Metrics
BasicAdvanced
$729M
-
-$5.86
1.51
-
Price and volume
Market cap
$729M
Beta
1.51
52-week high
$17.58
52-week low
$5.00
Average daily volume
1.7M
Financial strength
Current ratio
5.408
Quick ratio
5.137
Long term debt to equity
69.961
Total debt to equity
69.961
Interest coverage (TTM)
-3,135.87%
Profitability
EBITDA (TTM)
-230.792
Gross margin (TTM)
78.99%
Net profit margin (TTM)
-136.56%
Operating margin (TTM)
-127.71%
Effective tax rate (TTM)
0.28%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-12.90%
Return on equity (TTM)
-43.59%
Valuation
Price to revenue (TTM)
3.067
Price to book
1.19
Price to tangible book (TTM)
1.33
Price to free cash flow (TTM)
-2.582
Free cash flow yield (TTM)
-38.72%
Free cash flow per share (TTM)
-5.096
Growth
Revenue change (TTM)
25.21%
Earnings per share change (TTM)
-67.42%
3-year revenue growth (CAGR)
-24.63%
3-year earnings per share growth (CAGR)
-58.06%
Bulls say / Bears say
Ginkgo Bioworks reported first-quarter 2025 total revenue of $48 million, a 27% increase year-over-year, fueled by a 37% rise in its Cell Engineering segment to $38 million. (PRNewswire)
The company achieved $205 million in annualized cost savings and cut its quarterly cash burn by 44% to $58 million, demonstrating progress toward its $250 million cost-cutting goal. (Investing.com)
Ginkgo and its partners won a $29 million ARPA-H contract to develop decentralized manufacturing for essential medications using wheat germ cell-free expression systems. (PRNewswire)
Despite improvements, Ginkgo posted a GAAP net loss of $91 million in Q1 2025, highlighting continued unprofitability. (PRNewswire)
Biosecurity segment revenue held steady at $10 million in Q1 2025, showing stagnant demand after the pandemic. (PRNewswire)
Ginkgo’s RS Rating rose to 93, suggesting the stock is now extended beyond an optimal buy range and may need to consolidate before any further gains. (Investor’s Business Daily)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ginkgo Bioworks stock?
Ginkgo Bioworks (DNA) has a market cap of $729M as of October 14, 2025.
What is the P/E ratio for Ginkgo Bioworks stock?
The price to earnings (P/E) ratio for Ginkgo Bioworks (DNA) stock is 0 as of October 14, 2025.
Does Ginkgo Bioworks stock pay dividends?
No, Ginkgo Bioworks (DNA) stock does not pay dividends to its shareholders as of October 14, 2025.
When is the next Ginkgo Bioworks dividend payment date?
Ginkgo Bioworks (DNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Ginkgo Bioworks?
Ginkgo Bioworks (DNA) has a beta rating of 1.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.